HONG KONG and HANGZHOU, China, April 30, 2026 /PRNewswire/ -- Hangzhou Diagens Biotech Co., Ltd. (HKEX: 2526, "Diagens"), a pioneer in medical imaging foundation models, today announced its first annual results since its listing. The report marks a pivotal milestone in the company's transition from technical validation to large-scale commercialization, with annual revenue reaching RMB 164 million, a year-on-year increase of 133.7%.

Driven by the rapid adoption of its proprietary iMedImage® foundation model, Diagens saw its technology licensing revenue soar by 331.7% to RMB 84.34 million, officially becoming the company's primary growth engine. Gross profit reached RMB 118 million, with a robust margin of 71.8%, reflecting a high-value business model built on "Model-as-a-Service" (MaaS).

The Industrialization of Medical AI: From "Bespoke Projects" to "Mass Production"

The medical imaging sector accounts for approximately 80% of global clinical data, yet traditional AI has long struggled with "point solutions"—developing one model for one disease in a single modality. This fragmented approach results in long R&D ...